Boehringer Pharma Chief Confident Of Continued Success For Jardiance

SGLT2 Inhibitor Set For Further Expansion

Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.

Carinne Brouillon
Carinne Brouillon • Source: Boehringer Ingelheim

More from Strategy

More from Business